



## **JAGSONPAL PHARMACEUTICALS LIMITED**

Regd. Office. T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)  
Phone:0091-11-46181100, 46109900; Email: cs@jagsonpal.com  
CIN No.: L74899DL1978PLC009181

Date: November 19<sup>th</sup>, 2020

To,  
The Department of Corporate Services-  
Listing  
**BSE Ltd,**  
Phiroze Jeejeebhoy Towers,  
Dalai Street  
Mumbai-400 001

**Scrip Code: 507789**

To,  
The Department of Corporate Services-  
Listing  
**National Stock Exchange of India Ltd**  
Exchange Plaza, C-1, Block G,  
Bandra Kuria Complex,  
Bandra (E)  
Mumbai — 400 051  
**Symbol: JAGSNPHARM**

### **Sub: Clarification on Price Movement**

**Dear Sir/ Madam**

With reference to the clarification sought by you, please note that the Company is in compliant with all the necessary disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and all the material information/event which have bearing on the operation or performance of the Company which includes all price sensitive information are disseminated to the stock exchange well within the time by the Company.

Further, please note that we do not have any information or announcement (including pending announcement) which in our opinion may have a bearing on the price behavior of the Scrip. Therefore the movement in the Share price of the Company is purely due to Market Conditions and absolutely market driven and management of the Company is in no way connected with any such movement of price.

Hope this clarifies your query.

**For Jagsonpal Pharmaceuticals Limited**

**Nandita Singh**  
**Company Secretary and Compliance Officer**